ISebe leHlabathi

Ngomhla wama-25 ku-Epreli, ngo-2025, i-InnoCare Pharma ibhengeze ukuba isizukulwana sayo esitsha se-pan-TRK inhibitor zurletrectinib (ICP-723) sinikwe uphononongo oluphambili yiZiko loVavanyo lwaMayeza (CDE) le-China National Medical Products Administration (NMPA), elamkele isicelo se-New Drug Application (NDA) se-z...Funda ngokugqithisileyo»

Ngomhla wama-25 ku-Epreli, ngo-2025, i-Innovent Biologics ibhengeze ukuba i-National Medical Products Administration (NMPA) yaseTshayina ivumile isicelo esitsha se-limertinib njengonyango lokuqala kwizigulane zabantu abadala abanomhlaza wemiphunga ongekho mncinci (NSCLC) oqhubekekayo okanye osasazekayo...Funda ngokugqithisileyo»

Ngomhla wama-23 ku-Epreli, i-penpulimab ka-Akeso yafumana imvume kwi-Food and Drug Administration ene-cisplatin okanye i-carboplatin kunye ne-gemcitabine kunyango lokuqala lwabantu abadala abane-recurrent okanye i-metastatic non-keratinizing nasopharyngeal carcinoma (NPC). I-FDA ikwavumile i-penpulimab-kcqx njengesono...Funda ngokugqithisileyo»

Ngomhla we-16 kweyoKwindla, ngo-2025, u-Akeso ubhengeze ukuba i-antibody yayo entsha, ephuhlisiweyo ngokwayo, i-penpulimab, ivunyiwe ngokusesikweni yi-National Medical Products Administration (NMPA) yonyango lokuqala lomhlaza we-nasopharyngeal ophindaphindayo okanye osasazekayo (NPC) ngokudibeneyo ...Funda ngokugqithisileyo»

Ngomhla wama-24 ku-Epreli, ngo-2025, iGenFleet Therapeutics yabhengeza ukuba i-US Food and Drug Administration (FDA) ivumile ukusetyenziswa kweyeza elitsha (IND) le-GFH375/VS-7375, i-KRAS G12D (ON/OFF) inhibitor yomlomo, kuvavanyo lweklinikhi lokunyanga izigulane ezine-tumor eqinileyo eziguqukileyo ezine-mutation ye-KRAS G12D. Olu phononongo...Funda ngokugqithisileyo»

Ngomhla we-17 ku-Epreli, ngo-2025, iHansoh Pharmaceutical ibhengeze ukuba i-B7-H3-target antibody-drug conjugate (ADC) HS-20093 yeQela eyaziphuhlisa ngokwayo ukuze ijojwe ifumene imvume yokuba ifakwe njenge-Breakthrough-Therapy-Designed Drug yi-National Medical Products Administration (NMPA) yaseTshayina, ...Funda ngokugqithisileyo»

Ngomhla we-15 ku-Epreli, ngo-2025, i-InnoCare Pharma yabhengeza ukuba iZiko loVavanyo lwaMayeza (i-CDE) le-China National Medical Products Administration (i-NMPA) lamkele isicelo esitsha seyeza (i-NDA) kwisizukulwana sayo esitsha se-pan-TRK inhibitor zurletrectinib (ICP-723) yonyango lwabantu abadala nabakwishumi elivisayo...Funda ngokugqithisileyo»

Kutshanje, iGenFleet ibhengeze idatha yamva nje yesigaba sesiBini sophando lwe-KROCUS, i-fulzerasib (GFH925, i-KRAS G12C inhibitor) kunye ne-cetuximab yonyango lomhlaza wamaphaphu olungengolweseli encinci (NSCLC) lomgca wokuqala, kwisishwankathelo esisandula ukwenzeka kwintetho emfutshane yomlomo yeNgqungquthela yoMhlaza wamaphaphu yaseYurophu ka-2025...Funda ngokugqithisileyo»

I-PLB1004, eyenziwe yiBeijing Avistone Biotechnology Co., Ltd., sisixhobo esikhuselekileyo, esikhetha kakhulu, nesisebenzayo sokukhusela ukukhula kwe-epidermal factor receptor i-tyrosine kinase inhibitor (EGFR-TKI) esisetyenziswa ekunyangeni umhlaza wamaphaphu ongengoweeseli ezincinci (i-NSCLC). Ngomhla we-9 ku-Epreli, ngo-2025, iNational Medical Products Admi...Funda ngokugqithisileyo»

Ngomhla we-13 kweyoKwindla, ngo-2025, iphephancwadi lehlabathi eliphambili iNature Medicine lapapasha uvavanyo lweMediLink lwe-B7-H3 olujolise kwi-antibody drug conjugate (ADC) YL201 Phase 1/1b. Olu vavanyo lwaluquka inxalenye yokunyuka kwedosi (isigaba 1) kunye nenxalenye yokwandiswa kwedosi (isigaba 1b). Izigulane ezingama-312 zizonke zabhaliswa kulo lonke...Funda ngokugqithisileyo»

Ngomhla wama-21 kuMatshi 2025, i-Immunofoco yabhengeza ukuba unyango lwayo oluzimeleyo lwe-EpCAM olujolise kwi-autologous CAR-T cell therapy, i-IMC001, lunikwe imvume yiZiko loVavanyo lwaMayeza (i-CDE) phantsi koLawulo lweMveliso yezonyango lweSizwe (i-NMPA) eTshayina kwiD...Funda ngokugqithisileyo»

Ngomhla wama-31 kuMatshi 2025, i-Innovent Biologics ibhengeze ukuba iZiko loVavanyo lwaMayeza (i-CDE) le-National Medical Products Administration (i-NMPA) yaseTshayina linike iBreakthrough Therapy Designation (BTD) ye-IBI363, iprotheyini yokuqala ye-PD-1/IL-2α-bias bispecific antibody fusion protein, njenge-monotherapy ye...Funda ngokugqithisileyo»